Biosimilars are biological products such as proteins and antibodies that are highly analogous to FDA‐approved biologic reference products and have no clinically meaningful differences in terms of safety and effectiveness from reference products. Biosimilar monoclonal antibodies are an important part of the biosimilar family that can be used in the treatment of diseases like cancer and autoimmune disorders and is also important for research use.

 

Abeomics provides an array of biosimilar recombinant monoclonal antibodies that include Recombinant anti-human ErbB2/HER2 Antibody (Trastuzumab), Anti-Human CD11a (Efalizumab), Anti-Human CD194 (CCR4) (Mogamulizumab) and many more.